Article - 06/11/2017 HEIDELTEC: gummy bears may replace injections Peptide- and protein-based drugs like those used for treating diabetes, cancer and autoimmune diseases cannot be administered orally. This is because these biomolecules degrade in the gastrointestinal tract, thus preventing them from reaching their target site in the body. Protein- and peptide-base drugs therefore have to be administered by way of injection, which is comparatively complicated and painful. However, a start-up company called…https://www.gesundheitsindustrie-bw.de/en/article/news/heideltec-gummy-bears-may-replace-injections
Article - 08/08/2017 N2B-patch: circumventing the blood-brain barrier There are many medications for treating central nervous system diseases. However, only a fraction of the active pharmaceutical ingredients actually reaches the site where they are needed. The reason for this is the blood-brain barrier that protects the brain and thus prevents many drugs used to treat neurological diseases from effectively penetrating the brain. Researchers from the Fraunhofer Institute for Interfacial Engineering and…https://www.gesundheitsindustrie-bw.de/en/article/news/n2b-patch-circumventing-the-blood-brain-barrier
Article - 09/01/2017 Novaliq to develop innovative eye drop products A remedy is now available for people suffering from dry eye disease. Novaliq GmbH, a specialty pharmaceuticals company from Heidelberg, has developed a highly innovative technology platform for producing innovative drugs to eliminate common eye conditions that cause itching, burning and a feeling of pressure on the eye. The new drug delivery platform not only opens up groundbreaking new prospects for ophthalmology, but also for dermatology. https://www.gesundheitsindustrie-bw.de/en/article/news/novaliq-to-develop-innovative-eye-drop-products
Article - 13/09/2016 Catalent – galenics experts from Schorndorf Pharmaceutical and biotechnology companies are working intensively on the discovery and development of new drugs for the efficient and safe treatment of diseases. However, before drugs are authorised for treating humans and animals, they have to be made into a form that is acceptable. That is where a company called Catalent Pharma Solutions, with a facility in Schorndorf in the south of Germany, comes in.https://www.gesundheitsindustrie-bw.de/en/article/news/catalent-galenics-experts-from-schorndorf
Article - 02/08/2016 Can the ticking Huntington clock be stopped? An early phase clinical study involving thirty-six Huntington’s disease (HD) patients is currently underway to investigate whether a method called gene silencing can cure the disease. If the gene that causes the disease can be turned off, it would be the first step towards a treatment that not only fights symptoms but actually treats the causes of HD, hence providing a cure. Prof. Dr. G. Bernhard Landwehrmeyer, a neurologist from Ulm who is…https://www.gesundheitsindustrie-bw.de/en/article/news/can-the-ticking-huntington-clock-be-stopped
Article - 21/07/2016 New anticancer drugs – hop compounds have the potential to treat cancer Secondary hop compounds appear to have a positive effect on the immune system and therefore have the potential to be used for the treatment and prevention of cancer. However, the bioavailability of hop compounds in the human body is relatively poor. Researchers from Hohenheim and Tübingen are therefore looking for a way to increase their absorption rate.https://www.gesundheitsindustrie-bw.de/en/article/news/new-drugs-for-the-treatment-of-cancer-hop-compounds-have-the-potential-to-treat-cancer
Article - 02/05/2016 Biopolymers – raw materials for innovative medical products Polyhydroxyalkanoates (PHA) are biodegradable biopolymers that are becoming increasingly important. Bioplastics are now used not only in everyday objects such as plastic bags and yogurt pots but also increasingly in the field of medicine, which is why intensive research into medical devices made from biodegradable polymers such as PHA has been going on for quite some time. https://www.gesundheitsindustrie-bw.de/en/article/news/biopolymers-raw-materials-for-innovative-medical-products
Article - 04/04/2016 An intelligent system for the storage and controlled release of pharmaceutical substances It is no longer a pipe dream – a sophisticated reservoir that sits under the skin and dispenses precise quantities of drugs locally and at a particular point in time now exists. What's more, it is also biocompatible. A junior research group from the University of Freiburg’s BrainLinks-BrainTools excellence cluster led by Dr. Maria Asplund and her doctoral student Christian Böhler from the Department of Microsystems Engineering (IMTEK) has…https://www.gesundheitsindustrie-bw.de/en/article/news/an-intelligent-system-for-the-storage-and-controlled-release-of-pharmaceutical-substances
Article - 15/02/2016 Bacteria – a treasure box for genetic engineers Bacteria have developed a versatile defence system to protect themselves against viral infections. One of these defence tools, known as CRISPR/Cas9 system, is currently hogging the headlines as it promises to revolutionise the way genetic material can be modified. Prof. Rolf Backofen from the Institute of Bioinformatics at the University of Freiburg has managed to classify the defence system of all bacterial species sequenced to date. This will…https://www.gesundheitsindustrie-bw.de/en/article/news/bacteria-a-treasure-box-for-genetic-engineers
Article - 25/01/2016 And yet another biological from Biberach Boehringer Ingelheim is an important contract manufacturer of biopharmaceuticals that also produces proprietary drugs. The company’s last propriety biotech drug (tenecteplase) received marketing authorisation in 2001. The company has now placed another proprietary biopharmaceutical (idarucizumab) on the European and American markets and has a proprietary pipeline of monoclonal antibodies in late clinical development phases. We spoke with Dr.…https://www.gesundheitsindustrie-bw.de/en/article/news/and-yet-another-biological-from-biberach
Article - 26/11/2015 Chrystelle Mavoungou: how students get to the heart of the drug discovery process Chrystelle Mavoungou is a chemist who teaches regulatory affairs and quality in pharmaceutical production at the Biberach University of Applied Sciences’ Faculty of Biotechnology. While the public might consider these issues difficult to deal with, students and early career pharmaceutical biotechnologists quickly learn that issues like these take them right to the heart of the drug discovery process.https://www.gesundheitsindustrie-bw.de/en/article/news/chrystelle-mavoungou-how-students-get-to-the-heart-of-the-drug-discovery-process
Article - 05/10/2015 Nanoparticles make eye drops more effective Drops are a common way of applying drugs for treating a wide of range of eye diseases. Most of us have used eye drops at least once in our lives, but we are not usually aware that even if the drops are applied correctly, only one percent of the drug reaches the eye. The rest is flushed out by eyelid movement or with tear fluid. So very high drug concentrations are needed, and the downside of this is that it can cause substantial adverse effects.…https://www.gesundheitsindustrie-bw.de/en/article/news/nanoparticles-make-eye-drops-more-effective
Article - 22/06/2015 Through the nose directly into the brain: Biberach researchers are working on a novel way to apply pharmaceuticals The blood-brain barrier prevents most drugs, and large biologics in particular, from entering the brain. This physiological barrier impairs the study of central nervous system (CNS) diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis as well as the development of drugs. However, there is a hidden side entrance to the brain, which means that there is a way to circumvent this barrier.https://www.gesundheitsindustrie-bw.de/en/article/news/through-the-nose-directly-into-the-brain-biberach-researchers-are-working-on-a-novel-way-to-apply-pharmaceuticals
Overview Pharmaceutics The latest articles, press releases and dossiers on pharmaceutics in Baden-Württemberghttps://www.gesundheitsindustrie-bw.de/en/article/pharma
Article - 03/03/2014 Taking a drug taxi across the blood-brain barrier The central nervous system (CNS), which integrates the information it receives from all parts of the body, is perhaps the most sensitive organ we have. As toxic compounds are able to disturb brain function enormously, the brain is separated from circulating blood by a highly selective permeability barrier known as the blood-brain barrier. However, the downside of this protection is that 98 percent of all drugs targeting the CNS cannot pass the…https://www.gesundheitsindustrie-bw.de/en/article/news/taking-a-drug-taxi-across-the-blood-brain-barrier
Article - 03/02/2014 Verapido Medical GmbH: small needles with a huge effect Verapido Medical GmbH is a medical device company based in Villingen-Schwenningen (Germany) that develops and manufactures devices with which liquid drugs can be administered intradermally, i.e. into the skin rather than below the skin. The company’s microneedle technology looks to have several advantages over existing drug delivery methods, including better effect, less pain for the patient and lower costs. https://www.gesundheitsindustrie-bw.de/en/article/news/verapido-medical-gmbh-small-needles-with-a-huge-effect
Article - 16/04/2012 Pharma 2.0: towards paperless production Before electronic solutions existed, lorries were needed to ship new drug applications, which often comprised 500,000 or so pages. Thanks to IT, this is no longer necessary. IT-based procedures and solutions are playing an increasing role in all areas of the pharmaceutical industry. New IT technologies are constantly being developed for the different production steps, and legal guidelines are constantly being expanded. Markus Roemer, CEO of…https://www.gesundheitsindustrie-bw.de/en/article/news/pharma-2-0-towards-paperless-production
Press release - 16/11/2010 Nycomed is keeping the pace in third quarter 2010 - US Food & Drug Administration to decide on the approval of Daxas® Nycomed’s strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pantoprazole. Daxas® (roflumilast) has recently been launched in the first EU markets and further launches are underway over the coming months. To accelerate the expansion in China, one of the fastest…https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-is-keeping-the-pace-in-third-quarter-2010-us-food-drug-administration-to-decide-on-the-appro
Press release - 29/04/2010 Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® in Europe and Canada Nycomed and Merck & Co., Inc. announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD). Merck & Co., Inc. is based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-and-merck-co-inc-announce-commercialization-agreements-for-daxas-in-europe-and-canada
Press release - 20/04/2009 Help for coronary vessel constrictions – Tübingen cardiologists have developed an alternative to drug eluting stents Prof. Christian Herdeg at the University Hospital of Tübingen has developed an alternative approach for intracoronary pharmacotherapy for the treatment of patients with constricted coronary vessels. Localised drug delivery using special catheters is far superior to the use of uncoated stents and is also a way of avoiding the disadvantages of coated, i.e. drug eluting stents. For patients with existing or recurrent stenoses, the new method, which…https://www.gesundheitsindustrie-bw.de/en/article/press-release/help-for-coronary-vessel-constrictions-tuebingen-cardiologists-have-developed-an-alternative-to-drug
Article - 08/02/2008 Nycomed and Wyeth announce launch of an own generic version of PROTONIX® – lawsuit to defend patent continues Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), today announced the U.S. launch of an own generic version of PROTONIX® (Pantoprazole) tablets, in response to the at-risk launch of generic Pantoprazole tablets by Teva Pharmaceuticals USA, Inc. Today’s launch terminates the current standstill agreement between Nycomed, Wyeth and Teva.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-and-wyeth-announce-launch-of-an-own-generic-version-of-protonix-lawsuit-to-defend-patent-con
Database entry npi electronic GmbH For over 25 years npi electronic GmbH develops and produces equipment for research in the life sciences with main focus on neurosciences. Instruments include amplifiers, stimulus isolators, drug application systems, manipulators and temperature controllers. npi can also supply complete setups.